Epizyme Announces Pricing Of Public Offering Of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 13,333,334 shares of its common stock at a price of $9.00 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme. In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

Back to news